exendin-4-IgG4

**exendin-4-IgG4** is a recombinant fusion protein that combines exendin-4, a potent **glucagon-like peptide-1 (GLP-1) receptor agonist**, with the Fc fragment of human IgG4 to extend its half-life. The molecule is designed as a **long-acting GLP-1 receptor agonist** for the treatment of type 2 diabetes mellitus, aiming to improve glycemic control and increase patient compliance by reducing injection frequency. Mechanistically, exendin-4 stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, inhibits gastric emptying, and promotes beta-cell proliferation and survival. The IgG4 Fc fusion prolongs the drug’s half-life by reducing renal clearance, allowing for extended pharmacologic activity. The drug has been shown in early clinical trials to retain the native GLP-1 activity, provide effective glucose regulation, and maintain elevated plasma levels for over 200 hours after injection. Developed as a next-generation biologic, exendin-4-IgG4 is positioned as a candidate for longer-interval dosing in type 2 diabetes[2][5][8].

Other names

exendin-4-IgG4-Fcexendin4-IgG4-Fcexendin 4-IgG4-FcGLP-1-Exendin-4/IgG4 (Fc) fusion protein